T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

T2 Biosystems, a leader in rapid detection of sepsis-causing pathogens, announced its participation in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum.

Rhea-AI Summary

T2 Biosystems, a leader in rapid detection of sepsis-causing pathogens, announced its participation in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum. The presentation is scheduled for November 18, 2021, at 11:30 am ET. Interested stakeholders can access the live and recorded webcast on the company’s website. T2 Biosystems offers innovative products like the T2Dx Instrument and various pathogen detection panels, all powered by proprietary T2 Magnetic Resonance technology. The company aims to enhance patient care and reduce costs by enabling faster treatment.

Argus Session date unavailable

-0.70% session move Open Argus

Details

News Market Reaction – TTOO

The recorded move for TTOO in the trading session of this news was -0.70%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced plans to participate in the upcoming Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum.

Management is scheduled to present on Thursday, November 18, 2021, at 11:30am ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com.

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is T2 Biosystems presenting at the Canaccord Genuity Forum?

T2 Biosystems is scheduled to present on November 18, 2021, at 11:30 am ET.

Where can I watch T2 Biosystems' presentation?

You can access the webcast of T2 Biosystems' presentation on the Investors section of their website.

What products does T2 Biosystems offer?

T2 Biosystems offers products such as the T2Dx Instrument, T2Candida Panel, T2Bacteria Panel, T2Resistance Panel, and T2SARS-CoV-2 Panel.

What is the primary focus of T2 Biosystems?

T2 Biosystems focuses on the rapid detection of sepsis-causing pathogens to improve patient care and reduce costs.

What is the stock symbol for T2 Biosystems?

The stock symbol for T2 Biosystems is TTOO.